Medicover AB (0RPS) AI Stock Analysis

2 Followers

Medicover AB

(LSE:0RPS)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Organic growth and margin expansionSustained organic growth alongside repeated margin improvement indicates that Medicover is expanding its operating base while converting revenue into stronger profitability. Continued progress across multiple quarters supports durable earnings development and suggests the business can benefit from scale, pricing and operational discipline.

Negative Factors

Elevated leverageCurrent leverage remains a meaningful constraint despite expected improvement from the India transaction. Debt funding can amplify earnings volatility, increase financial risk and limit flexibility for investment or acquisitions if operating performance weakens or revenue growth remains subdued.

Medicover AB (0RPS) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 39.67B
Dividend Yield: 0.83%
Average Volume (3M): 16.57K
Price to Earnings (P/E): 39.8
Beta (1Y): 0.93
Revenue Growth: 2.62%
EPS Growth: 31.56%
Country: UK
Employees: 49,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Medicover AB Business Overview & Revenue Model

Company Description

Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turke...

Medicover AB Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-4.81%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentPositive

The call was predominantly positive. Management reported sustained organic growth, seven consecutive quarters of year-on-year margin improvement, stronger profitability, improved leverage, a significant India divestment expected to generate approximately EUR 740 million, and continued expansion in Sports and Wellness and Diagnostics. The company acknowledged several near-term challenges, including German genetics reimbursement reform, softer German Diagnostics activity, slower Romanian membership and hospital performance, FX pressure and temporary revenue effects from site changes and prior pricing decisions. Management repeatedly characterized these issues as manageable or temporary and maintained its targets.

Positive Updates

Consistent Growth and Seventh Consecutive Quarter of Margin Improvement

Management described another consistent quarter, with 8% organic growth on continuing operations and year-on-year margin improvement for the seventh consecutive quarter. Total revenue was up 6% on a continuing basis, while the company stated that total revenue including India was up 8% versus Q2 and organic revenue was double digit on that basis.

Negative Updates

Negative Foreign-Exchange Impact

Organic growth was affected by a 2% negative FX impact. Management said approximately half of the FX drag came from the Polish zloty and that the balance was predominantly from Romania.

Company Guidance

Management expects the India transaction to close sometime in November, or it will close in Q4, with India expected not to be in the numbers from Q1 next year onwards; it stands by the targets that have been set before for now. Full-year CapEx will still be between 6% to 6.5% of revenues, the effective tax rate will be between 26% to 30% for the year, and German genetics reimbursement changes are expected to be managed over the course of the next four quarters. B2B growth should start to come through as the full cycle progresses, membership growth is expected to come back, and the company expects new Sports and Wellness facilities to continue opening in Q4 and beyond.

Medicover AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0RPS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:ATT	74Outperform	SEK 19.02B	18.66	―	1.36%	0.24%	61.96%
SE:AMBEA	71Outperform	SEK 16.39B	18.48	16.80%	1.36%	11.39%	30.51%
SE:CARE	71Outperform	SEK 737.08M	15.05	―	―	12.86%	18.01%
SE:ASKER	67Neutral	SEK 27.93B	37.79	―	0.52%	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0RPS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0RPS	Medicover	262.25	29.20	12.53%
SE:ATT	Attendo AB	132.70	52.46	65.38%
SE:AMBEA	Ambea AB	195.50	70.00	55.78%
SE:CARE	Careium AB	30.70	5.70	22.80%
SE:ASKER	Asker Healthcare Group AB	74.45	-19.39	-20.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Medicover AB AI Stock Analysis